List of Excipients in Branded Drug CALAN SR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	CALAN SR	verapamil hydrochloride	0025-1901	CARNAUBA WAX
Pfizer Laboratories Div Pfizer Inc	CALAN SR	verapamil hydrochloride	0025-1901	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	CALAN SR	verapamil hydrochloride	0025-1901	HYPROMELLOSE
Pfizer Laboratories Div Pfizer Inc	CALAN SR	verapamil hydrochloride	0025-1901	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	CALAN SR	verapamil hydrochloride	0025-1901	POLYETHYLENE GLYCOL

Calan SR Excipient Strategy and Commercial Opportunities for Verapamil Extended-Release Tablets

Last updated: September 24, 2026

Calan SR is an extended-release tablet containing verapamil hydrochloride, a calcium-channel blocker used primarily for hypertension, angina, and certain supraventricular arrhythmias. Its core commercial opportunity is not brand exclusivity. It is the development of lower-cost generic products, differentiated extended-release platforms, 505(b)(2) products, and excipient systems that improve release consistency, manufacturability, tolerability, or global regulatory acceptability.

The most important technical issue is controlled release of a highly soluble, pharmacologically active drug while maintaining dose proportionality across 120 mg, 180 mg, and 240 mg strengths. The most valuable excipient work is likely to involve polymer selection, matrix robustness, manufacturing process control, and reduction of formulation variability rather than discovery of a new active pharmaceutical ingredient.

What is Calan SR and how does its formulation work?

Calan SR contains verapamil hydrochloride in a sustained-release tablet. The dosage form releases verapamil more slowly than immediate-release tablets, reducing peak-to-trough fluctuations and allowing less frequent administration.

Calan SR is distinct from other verapamil products:

Product	Active ingredient	Release type	Typical commercial positioning
Calan tablets	Verapamil hydrochloride	Immediate release	Multiple daily dosing
Calan SR	Verapamil hydrochloride	Sustained release	Extended-release tablet
Isoptin SR	Verapamil hydrochloride	Sustained release	International sustained-release product
Verelan	Verapamil hydrochloride	Extended release	Alternative extended-release technology
Verelan PM	Verapamil hydrochloride	Extended release with chronotherapeutic positioning	Bedtime administration and delayed release

Calan SR should not be treated as interchangeable from a formulation perspective with Verelan PM. Both contain verapamil, but their release profiles, dosing instructions, formulation technologies, and regulatory histories differ.

The FDA labeling for Calan SR identifies inactive ingredients used to construct the tablet matrix, improve compression, control hydration, provide lubrication, and support coating or appearance. Formulation details should be assessed against the current product label and the applicable reference listed drug record because excipient composition can change over a product’s commercial life. (U.S. Food and Drug Administration [FDA], n.d.-a)

What excipients are relevant to a Calan SR formulation?

The principal excipient categories for a verapamil sustained-release tablet are shown below.

Excipient function	Relevant materials	Commercial purpose
Release-controlling polymer	Hypromellose, sodium alginate, other hydrophilic polymers	Controls water penetration, gel formation, and drug diffusion
Matrix former and diluent	Microcrystalline cellulose, dibasic calcium phosphate, lactose or other fillers	Provides tablet mass, mechanical strength, and manufacturability
Binder	Povidone and related binders	Improves granule cohesion and tablet hardness
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide or comparable materials	Improves powder flow and blend uniformity
Coating materials	Hypromellose, polyethylene glycol, titanium dioxide, talc, colorants	Supports identification, handling, appearance, and moisture protection
Hydration and gel modifiers	Alginates and polymer combinations	Adjusts release rate and reduces sensitivity to compression conditions

The best excipient strategy depends on the intended regulatory pathway. An ANDA applicant generally seeks pharmaceutical equivalence and bioequivalence to the reference product. A 505(b)(2) applicant can pursue a modified release profile, dosing schedule, strength, or delivery system if the product has a defensible clinical and regulatory rationale. (FDA, 2023)

Why hypromellose and alginate systems are commercially important

Hydrophilic matrix systems are attractive for verapamil because they can be manufactured with conventional wet granulation, dry granulation, or direct-compression processes. Their performance depends on:

• Polymer viscosity grade
• Polymer concentration
• Particle-size distribution
• Drug-to-polymer ratio
• Tablet hardness and porosity
• Granulation endpoint
• Dissolution medium and agitation conditions
• Coating weight and moisture permeability

Hypromellose creates a hydrated gel layer after contact with gastrointestinal fluid. The gel controls diffusion and erosion. Sodium alginate can modify hydration, swelling, and gel strength. Combining polymers may reduce the risk that one material dominates the release profile across different tablet strengths.

A formulation that uses too little high-viscosity polymer can release verapamil too rapidly. Excess polymer can delay release, increase tablet size, create manufacturing problems, or produce a dissolution profile that diverges from the reference product.

What excipient risks affect commercial development of Calan SR generics?

The principal risks are dose dumping, dissolution variability, food effects, excipient supply disruption, and failure to match the reference product across the full dissolution profile.

Dose dumping and release-profile failure

Verapamil is pharmacologically active at relatively low plasma concentrations, and excessive early release can increase cardiovascular safety risk. Development programs should evaluate release behavior under:

• Alcohol exposure
• High-fat meals
• Fasted conditions
• Multiple pH environments
• Different agitation rates
• Compression-force ranges
• Accelerated stability conditions

Alcohol-induced dose dumping is a recognized concern for modified-release products. A robust matrix should maintain acceptable release behavior in alcohol-containing dissolution media where the regulatory program requires such testing.

Food-effect and gastrointestinal variability

A polymer matrix that depends heavily on hydration can respond differently to fed and fasted gastrointestinal conditions. The product should be evaluated for:

• Gastric emptying variability
• Tablet transit time
• Food-induced changes in fluid volume and motility
• pH-dependent polymer behavior
• Differences between strengths

A formulation with excessive sensitivity to food may require more restrictive labeling, reducing commercial competitiveness.

Excipient supply and quality

Large-volume generic manufacturers generally prefer excipients with multiple qualified suppliers. A patented formulation that relies on a single high-viscosity polymer grade may create supply risk and weaken the commercial case.

The preferred excipient platform should have:

• At least two qualified sources where feasible
• Compendial compliance
• Stable particle-size and viscosity specifications
• Low lot-to-lot variability
• Established global regulatory acceptance
• Limited dependence on animal-derived materials
• Low nitrosamine and elemental-impurity risk

What patents protect Calan SR and verapamil sustained-release products?

The original composition-of-matter protection for verapamil is expired. The commercial patent question therefore concerns formulation, release profile, manufacturing process, and method-of-use claims rather than the active molecule.

The original verapamil patent was issued decades ago and cannot provide current market exclusivity for Calan SR. Current generic competition is governed primarily by FDA approval status, reference-product designation, formulation equivalence, and any surviving product-specific patents listed in the Orange Book. (U.S. Patent and Trademark Office, 1966; FDA, n.d.-b)

Potentially relevant patent categories include:

Patent category	Potential claim scope	Commercial relevance
Matrix composition	Verapamil with a specified polymer ratio	Can support formulation differentiation
Release profile	Defined dissolution windows or pharmacokinetic parameters	Useful where the profile has clinical or regulatory value
Coating technology	Barrier or functional coating controlling release	May protect manufacturing and performance
Manufacturing process	Granulation, compression, curing, or coating conditions	Can create process-based barriers
Dosage regimen	Timing or dosing schedule	Relevant to 505(b)(2) development
Combination therapy	Verapamil combined with another active ingredient	May create a new product opportunity
Patient subgroup	Use in a defined clinical population	Requires credible clinical support

A formulation patent is strongest when it links a narrowly defined excipient system to a measurable technical result, such as improved dissolution reproducibility, reduced food effect, reduced alcohol sensitivity, or a clinically meaningful pharmacokinetic advantage. Broad claims covering ordinary use of hypromellose, alginate, povidone, or magnesium stearate are more vulnerable to prior-art and obviousness challenges.

What is the Orange Book status of Calan SR?

Calan SR is a prescription extended-release verapamil product associated with an FDA-approved new drug application. The Orange Book identifies reference-listed-drug and approved-product information, including dosage form, strength, applicant, and patent or exclusivity information where applicable. (FDA, n.d.-b)

The key regulatory points are:

1. The active ingredient is verapamil hydrochloride.
2. The relevant dosage form is an extended-release or sustained-release tablet.
3. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.
4. A 505(b)(2) applicant may pursue a differentiated release profile or administration schedule.
5. Product-specific patent and exclusivity status must be confirmed against the current Orange Book entry and FDA approval records.

The original molecule does not create a current regulatory exclusivity barrier. Any practical barrier is more likely to arise from reference-product selection, bioequivalence complexity, manufacturing capability, or formulation-specific patents.

When does Calan SR lose exclusivity?

Calan SR’s active-ingredient patent exclusivity has expired. The product is therefore exposed to generic competition, subject to FDA approval and the regulatory status of individual applicants.

For a legacy product such as Calan SR, the relevant exclusivity analysis is:

Exclusivity type	Current commercial relevance
Verapamil composition-of-matter patent	Expired
Original product patent estate	Largely historical
New formulation patents	Relevant only if unexpired and listed or enforceable
New chemical entity exclusivity	Expired
Orphan exclusivity	Not the core protection for Calan SR
Pediatric exclusivity	Not a durable current barrier
ANDA first-filer exclusivity	Potentially relevant to individual generic applicants

A Paragraph IV certification may be filed if an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. Where no enforceable listed patent remains, the principal pathway is ordinary ANDA review rather than patent litigation.

Which companies are challenging or competing with Calan SR?

Competition comes from generic verapamil manufacturers and from alternative extended-release products rather than from a single direct brand challenger. Generic competition can include products marketed under company labels by large manufacturers, specialty-generic companies, and contract-manufacturing partners.

The competitive set includes:

• Generic verapamil sustained-release tablets
• Generic verapamil extended-release capsules or tablets, where approved
• Immediate-release verapamil products
• Other calcium-channel blockers, including diltiazem and amlodipine
• Alternative therapies for hypertension, angina, and supraventricular tachycardia

The strongest direct competitors are products with:

• The same strength
• The same release category
• Comparable dosing frequency
• FDA-rated therapeutic equivalence
• Reliable supply
• Competitive reimbursement status

A generic with equivalent clinical performance but fewer supply interruptions can capture share even without a novel excipient platform.

What commercial opportunities exist for Calan SR excipient innovation?

1. Low-cost ANDA platform

The lowest-risk opportunity is a conventional hydrophilic matrix tablet using widely available compendial excipients. The commercial objective is to achieve bioequivalence with low manufacturing cost and a reliable dissolution profile.

The main value drivers are:

• High tablet yield
• Short production cycle
• Low rejection rate
• Strong content uniformity
• Stable dissolution across lots
• Multiple qualified excipient suppliers

2. 505(b)(2) modified-release product

A 505(b)(2) product could target:

• Once-daily administration
• Reduced food effect
• Lower peak concentration
• Improved nighttime or chronotherapeutic dosing
• A new strength
• A different dosage form
• Improved swallowing characteristics

This pathway offers more differentiation but requires a stronger clinical and pharmacokinetic rationale than a conventional ANDA.

3. Abuse-resistant or alcohol-resistant release platform

Verapamil is not generally positioned as a high-abuse product, so abuse deterrence may not justify development cost. Alcohol-resistant release, by contrast, can have a clearer quality and safety rationale if it produces a meaningful improvement in release robustness.

A patentable opportunity may exist around a matrix-coating combination that maintains dissolution performance across alcohol exposure without excessive tablet size or manufacturing complexity.

4. Patient-friendly dosage forms

Potential differentiated products include:

• Smaller high-load tablets
• Sprinkleable multiparticulates
• Orally disintegrating systems with controlled-release particles
• Swallowing-friendly coated granules
• Products designed for patients with dysphagia

These products could support a 505(b)(2) strategy if they provide a clinically relevant administration benefit.

5. Global excipient harmonization

A formulation designed for simultaneous U.S., European, and emerging-market registration can reduce development cost. The preferred platform should minimize reliance on colorants, animal-derived ingredients, or excipients with limited regional acceptance.

Geographic expansion is most practical where:

• The reference product remains commercially relevant
• Local generic competition is limited
• Verapamil is included in national formularies
• The product can be manufactured without country-specific excipient reformulation

How strong is the patent estate for a new Calan SR formulation?

A new Calan SR formulation can have moderate patent strength if it combines a defined polymer system with a measurable performance advantage. Patent strength is weaker when the claims merely recite conventional excipients at routine concentrations.

A strong estate would contain:

1. Composition claims covering the active ingredient and polymer ranges.
2. Dissolution claims tied to defined testing conditions.
3. Manufacturing claims covering granulation, compression, and coating.
4. Pharmacokinetic claims covering reduced variability or improved exposure.
5. Method-of-use claims linked to the modified release profile.
6. Backup claims using alternative polymers and excipient grades.

The patent program should separate platform claims from product-specific claims. Platform claims can support multiple drugs, while product claims can provide stronger protection around verapamil’s specific release behavior.

What generic launch risks exist for Calan SR?

Generic launch risk is moderate rather than high because the molecule is old and the principal formulation technologies are established. The main risks are regulatory execution and commercial economics.

Risk	Impact
Failure to match dissolution profile	ANDA delay or additional studies
Food-effect mismatch	Labeling restrictions or bioequivalence failure
Polymer lot variability	Batch-to-batch release differences
Low market price	Weak return on development investment
Reference-product ambiguity	Increased regulatory complexity
Limited demand	Low manufacturing scale
Supply interruption	Loss of pharmacy and wholesaler share
Formulation patent challenge	Litigation or delayed launch
Physician familiarity with alternatives	Slower adoption of differentiated products

Revenue exposure for the legacy brand is difficult to assess without current net sales, payer data, and product availability. The relevant commercial metric is the size and persistence of the verapamil extended-release market, not historical Calan SR sales alone. A generic entrant should model price erosion, wholesaler discounts, channel concentration, and the number of approved competitors.

Key Takeaways

• Calan SR is a verapamil hydrochloride sustained-release tablet.
• Its core formulation challenge is controlled release of a soluble cardiovascular drug across multiple strengths.
• Hypromellose, alginate, microcrystalline cellulose, povidone, magnesium stearate, and coating excipients are central to development strategy.
• The original verapamil patent estate is expired; current opportunity lies in generic substitution and differentiated formulations.
• A conventional ANDA is the lowest-risk route but offers limited product differentiation.
• A 505(b)(2) product could target once-daily dosing, reduced food effect, improved swallowing, or a distinct release profile.
• The strongest formulation patents should claim defined excipient ranges linked to measurable dissolution or pharmacokinetic advantages.
• Commercial success will depend more on cost, supply reliability, regulatory execution, and reimbursement than on molecule-level exclusivity.

FAQs

Is Calan SR the same as Verelan PM?

No. Both contain verapamil hydrochloride, but their release technologies, dosing instructions, pharmacokinetic profiles, and regulatory records differ.

Can hypromellose be used in a generic Calan SR tablet?

Yes. Hypromellose is a standard controlled-release polymer. The selected viscosity grade, concentration, particle properties, and processing conditions must produce an acceptable release profile and support bioequivalence.

Does verapamil have active composition-of-matter patent protection?

No. The original composition-of-matter protection for verapamil expired decades ago.

Can a new excipient combination qualify for a 505(b)(2) application?

Potentially. The product must present a meaningful difference from the reference product and provide appropriate safety, efficacy, and pharmacokinetic support.

What is the most defensible commercial strategy for a new Calan SR competitor?

A cost-efficient ANDA is the most direct strategy. A 505(b)(2) product has greater upside when it can demonstrate a clinically relevant benefit such as once-daily administration, reduced food sensitivity, improved release robustness, or easier administration.

References

1. U.S. Food and Drug Administration. (n.d.-a). Calan SR prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA Center for Drug Evaluation and Research.

4. U.S. Patent and Trademark Office. (1966). U.S. Patent No. 3,261,859: Benzene derivatives. Washington, DC.